Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Isis Pharmaceuticals reports phase I data on ISIS-TTRRx

Jan. 12, 2012

KalVista Pharmaceuticals and JDRF enter partnership

Jan. 11, 2012

Amicus Therapeutics presents results from phase II study in Fabry's disease

Jan. 11, 2012

BioCryst reports on extension phase of BCX-4208 trial

Jan. 11, 2012

Alnylam files ALN-TTR02 CTA with MHRA

Jan. 10, 2012

Phase II trial of diabetes vaccine reaches full enrollment

Jan. 10, 2012

Scientists at Merck & Co. prepare new PRCP inhibitors

Jan. 10, 2012

KAI Pharmaceuticals begins recruitment in second phase II study of KAI-4169

Jan. 10, 2012

FDA accepts Repros Therapeutics' IND for Proellex-V

Jan. 9, 2012

Alnylam reports preliminary results from phase I ALN-PCS trial

Jan. 5, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...